Skip to main content
Top

2018 | OriginalPaper | Hoofdstuk

10. Droge ogen

Auteur : Dr. R. P. Rietveld

Gepubliceerd in: Therapie van alledaagse klachten

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting beleid

Het droge-ogensyndroom komt veel voor en de incidentie neemt toe met het vorderen van de leeftijd. Het is een hinderlijk beeld dat een aanzienlijke ziektelast geeft. Met behulp van anamnese en onderzoek van het uitwendige oog kunnen behandelbare dan wel ernstige oorzaken worden uitgesloten. Als er geen aanwijzingen zijn voor een specifieke oorzaak spreken we van het droge-ogensyndroom. Attendeer patiënten op de uitleg en adviezen van www.​thuisarts.​nl/​droge-ogen/​ik-heb-droge-ogen. Het verbeteren van omgevingsfactoren kan leiden tot verbetering van de klachten. Adviseer de patiënt rokerige ruimtes, airconditioned ruimtes, ventilatoren, haarföhnen en contactlenzen te vermijden. Adviseer daarnaast verbetering van de luchtvochtigheid door waterbakken op de verwarming of een luchtbevochtiger. In sommige gevallen kan een afsluitende bril de vochtigheid van de ogen bevorderen. Adviseer frequent knipperen bij langdurig lezen of beeldschermgebruik. De klachten verminderen doorgaans door het gebruik van kunsttranen zoals carbomeerooggel of hypromelloseoogdruppels, zo nodig 3–4 dd 1 druppel. Omdat het effect van de verschillende kunsttranen sterk individueel bepaald is, kan bij onvoldoende resultaat een ander preparaat worden geprobeerd. In sommige gevallen kunnen kunsttranen overdag gecombineerd worden met oculentum simplex oogzalf voor de nacht. Bij ernstige klachten waarbij vaak moet worden gedruppeld, hebben conserveermiddelvrije middelen de voorkeur. Bij contactlenzen kan de kunsttraan met de contactlens reageren en door de contactlens opgenomen worden, wat leidt tot irritatie. Vooral zachte lenzen zijn hiervoor gevoelig. Conserveermiddelvrije middelen hebben dan de voorkeur. Daarnaast kan een dieet geadviseerd worden waarbij voldoende omega 3- en 6-vetzuren wordt ingenomen. Inname van antioxidanten als voedingssupplement kan ook geprobeerd worden. Verwijs bij hardnekkige klachten de patiënt naar de oogarts voor een tweedelijnsbehandeling.
Literatuur
1.
go back to reference Rietveld RP, Cleveringa JP, Blom GH, et al. NHG-Standaard Het Rode Oog (eerste herziening). Huisarts Wet. 2006; 78–9. Rietveld RP, Cleveringa JP, Blom GH, et al. NHG-Standaard Het Rode Oog (eerste herziening). Huisarts Wet. 2006; 78–9.
2.
go back to reference Hoogsteder PHJ, Hautermans K. Droge ogen. Huisarts Wet. 2013; 489. Hoogsteder PHJ, Hautermans K. Droge ogen. Huisarts Wet. 2013; 489.
5.
go back to reference Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol. 1988;23:174.PubMed Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol. 1988;23:174.PubMed
6.
7.
go back to reference Drugs for some common eye disorders. Treat Guidel Med Lett. 2010;8:1. Drugs for some common eye disorders. Treat Guidel Med Lett. 2010;8:1.
8.
go back to reference Nilforoushan MR, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol. 2005;140:830.CrossRefPubMed Nilforoushan MR, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol. 2005;140:830.CrossRefPubMed
10.
go back to reference Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046.CrossRefPubMed Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046.CrossRefPubMed
11.
go back to reference Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631.CrossRefPubMed Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631.CrossRefPubMed
12.
go back to reference Baiza-Durán L, Medrano-Palafox J, Hernández-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94:1312.CrossRefPubMed Baiza-Durán L, Medrano-Palafox J, Hernández-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94:1312.CrossRefPubMed
13.
go back to reference Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98:1016.CrossRefPubMed Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98:1016.CrossRefPubMed
14.
go back to reference Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35:741.CrossRefPubMedPubMedCentral Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35:741.CrossRefPubMedPubMedCentral
15.
go back to reference Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121:475.CrossRefPubMed Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121:475.CrossRefPubMed
16.
go back to reference Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015;122:2423.CrossRefPubMed Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015;122:2423.CrossRefPubMed
17.
go back to reference Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153:1050.CrossRefPubMed Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153:1050.CrossRefPubMed
18.
go back to reference Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol. 2010;149:594.CrossRefPubMed Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol. 2010;149:594.CrossRefPubMed
19.
go back to reference Jonisch J, Steiner A, Udell IJ. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea. 2010;29:723–6.CrossRefPubMed Jonisch J, Steiner A, Udell IJ. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea. 2010;29:723–6.CrossRefPubMed
20.
go back to reference Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. 2014;55:203–8.CrossRefPubMed Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. 2014;55:203–8.CrossRefPubMed
21.
go back to reference Sainz de la Maza Serra SM. Simon Castellvi C, Kabbani O. Nonpreserved topical steroids and punctual occlusion for severe keratoconjunctivitis sicca. Arch Soc Esp Oftalmol. 2000;75:751–6. Sainz de la Maza Serra SM. Simon Castellvi C, Kabbani O. Nonpreserved topical steroids and punctual occlusion for severe keratoconjunctivitis sicca. Arch Soc Esp Oftalmol. 2000;75:751–6.
22.
go back to reference Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;8:675–8.CrossRef Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;8:675–8.CrossRef
23.
go back to reference Byun YJ, Kim TI, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012;31:509–13.CrossRefPubMed Byun YJ, Kim TI, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012;31:509–13.CrossRefPubMed
24.
go back to reference Moore QL, De Paiva CS, Pflugfelder SC. Effects of dry eye therapies on environmentally induced ocular surface disease. Am J Ophthalmol. 2015;160:135–42.CrossRefPubMedPubMedCentral Moore QL, De Paiva CS, Pflugfelder SC. Effects of dry eye therapies on environmentally induced ocular surface disease. Am J Ophthalmol. 2015;160:135–42.CrossRefPubMedPubMedCentral
25.
go back to reference Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;163:593–602.CrossRef Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;163:593–602.CrossRef
26.
go back to reference Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–57.CrossRefPubMed Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–57.CrossRefPubMed
27.
go back to reference Lee HK, Ryu IH, Seo KY, et al. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113:198–205.CrossRefPubMed Lee HK, Ryu IH, Seo KY, et al. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113:198–205.CrossRefPubMed
28.
go back to reference Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol. 2011;5:633–43.PubMedPubMedCentral Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol. 2011;5:633–43.PubMedPubMedCentral
29.
go back to reference Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40:289–96.CrossRefPubMed Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40:289–96.CrossRefPubMed
31.
go back to reference Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100:22.CrossRefPubMed Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100:22.CrossRefPubMed
32.
go back to reference Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis. 2003;62:1204.CrossRefPubMedPubMedCentral Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis. 2003;62:1204.CrossRefPubMedPubMedCentral
33.
go back to reference Miljanović B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82:887.PubMedPubMedCentral Miljanović B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82:887.PubMedPubMedCentral
34.
go back to reference Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008;31:141.CrossRefPubMed Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008;31:141.CrossRefPubMed
35.
go back to reference Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30:308.CrossRefPubMed Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30:308.CrossRefPubMed
36.
go back to reference Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013;120:2191.CrossRefPubMed Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013;120:2191.CrossRefPubMed
37.
go back to reference Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219.CrossRefPubMed Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219.CrossRefPubMed
38.
go back to reference Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol. 2009;19:337.PubMed Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol. 2009;19:337.PubMed
39.
go back to reference Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr. 2001;55:589.CrossRefPubMed Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr. 2001;55:589.CrossRefPubMed
40.
go back to reference Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147:206.CrossRefPubMed Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147:206.CrossRefPubMed
41.
go back to reference Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2010;CD006775. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2010;CD006775.
42.
go back to reference Bavinger JC1, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. Curr Opin Ophthalmol. 2015;26(4):319. Bavinger JC1, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. Curr Opin Ophthalmol. 2015;26(4):319.
43.
go back to reference Tseng KL, Liu HJ, Tso KY, et al. A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome. Am J Chin Med. 2006;34:197.CrossRefPubMed Tseng KL, Liu HJ, Tso KY, et al. A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome. Am J Chin Med. 2006;34:197.CrossRefPubMed
44.
go back to reference Grönlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keatoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand. 2004;82:283. Grönlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keatoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand. 2004;82:283.
Metagegevens
Titel
Droge ogen
Auteur
Dr. R. P. Rietveld
Copyright
2018
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-1922-0_10